Criteria to qualify for study: Drug used in study:
  • Must have been treated with at least 1 prior therapy.

HEMREF 48 - H3B-8800-101 H3 Biomedicine and Eisai

An Open-Label Multicenter Phase I trial to evaluate the Safety, Pharmacokynetics and Pharmacodynamic of Splicing Modulator H3B-800 for Subjects with CMML.